Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

समान संसाधन

• Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
  द्वारा: Janssen, R. A., और अन्य
  प्रकाशित: (1992)
• Prolonged continuous infusion of low-dose rIL-2.
  द्वारा: Janssen, R. A., और अन्य
  प्रकाशित: (1994)
• Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
  द्वारा: Kroesen, B. J., और अन्य
  प्रकाशित: (1994)
• sCD14, IL-6 and TNF-receptors, but not IL-1, IL-8 or TNF-α are elevated in plasma of patients undergoing high risk coronary angioplasty with cardiopulmonary support
  द्वारा: Prondzinsky, R, और अन्य
  प्रकाशित: (1999)
• Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
  द्वारा: Geertsen, P F, और अन्य
  प्रकाशित: (2004)